益生菌干预治疗对非小细胞肺癌化疗患者肠道菌群、免疫功能及相关并发症的影响

目的:研究观察益生菌干预治疗对非小细胞肺癌化疗患者肠道菌群、免疫指标及相关并发症的影响。方法:选取自2016年1月-2018年12月赤峰学院附属医院收诊的80例非小细胞肺癌(NSCLC)需要化疗患者作为观察对象,将其随机分为益生菌给药组及安慰剂对照组,每组各40例。测量两组患者化疗前后体格指标,观察患者化疗相关并发症的发生情况,定量检测治疗前后双歧杆菌属、乳酸杆菌属、大肠杆菌和肠球菌属,血清CD3^+、CD4^+、CD8^+T细胞水平,粪便悬浮液中的粪便SIg A含量的变化。结果:化疗后,益生菌给药组患者的BMI、WHR均显著高于安慰剂对照组(P<0.05);益生菌给药组的双歧杆菌、乳酸杆菌含量及粪便SIg A含量与安慰剂对照组相比显著增加,肠球菌、大肠杆菌的含量显著减少(P<0.05);化疗后,益生菌给药组CD3^+、CD4^+T细胞比例显著增加(P<0.05),CD8^+T细胞比例显著下降(P<0.05),安慰剂对照组无明显改善(P>0.05);益生菌给药组的CD4^+/CD8^+比例与安慰剂对照组相比较显著升高(P<0.05)。结论:益生菌干预能调节NSCLC化疗患者的肠道菌群失衡,提高其免疫功能,并减少患者化疗期间相关并发症。

Effect of Probiotic Intervention on the Intestinal Flora, Immune Indexes and Related Complications in Patients with Non-small Cell Lung Cancer Undergoing Chemotherapy

ABSTRACT Objective: To observe the effect of probiotic intervention on intestinal flora, immune indexes and related complications in patients with non-small cell lung cancer undergoing chemotherapy. Methods: 80 patients with non-small cell lung cancer (NSCLC) who needed chemotherapy from January 2016 to December 2018in affiliated hospital of Chifeng universitywere selected as the subjects of observation. They were randomly divided into probiotics group and placebo control group with 40 patients in each group. The physical indexes of each group were measured before and after chemotherapy. The occurrence of complications related to chemotherapy was observed. Bifidobacterium, Lactobacillus, Escherichia coli and Enterococcus were detected quantitatively. The levels of CD3⁺, CD4⁺, CD8⁺ T cells in serum and SIgA in fecal suspension were measured. Results: After chemotherapy, the BMI and WHR of the probiotics group were significantly higher than those of the placebo group (P<0.05). The contents of bifidobacteria, lactobacillus and fecal SIgA in the probiotics group were significantly increased compared with the placebo group, and the contents of enterococci and escherichia coli were significantly reduced (P<0.05). After chemotherapy, the proportion of CD3⁺ and CD4⁺T cells in the probiotics group increased significantly (P<0.05), while the proportion of CD8⁺T cells decreased significantly (P<0.05), and there was no significant improvement in the placebo group (P>0.05). The ratio of CD4⁺/CD8⁺ in the probiotics group was significantly higher than that in the placebo group (P<0.05). Conclusion: The balance of intestinal flora in NSCLC patients was destroyed after chemotherapy. Probiotics intervention can regulate the imbalance of intestinal flora, improve the immune status of patients, and reduce the complications during chemotherapy.